Although recent reports have highlighted how bullous pemphigoid (BP) is induced by dipeptidyl peptidase-4 inhibitors (DPP4i), they provide little information on how pemphigus vulgaris (PV) may be induced by DPP4i.1 Herein, we report a case of PV that developed in a patient treated with sitagliptin for type 2 diabetes mellitus. In this case, the titer of the anti-desmoglein (DSG) 3 antibody immediately decreased after cessation of sitagliptin treatment, but the titer of anti-DSG1 antibody was maintained.
Handa T, Kamiya T, Sumikawa Y, et al. Decrease of Anti-DSG3, but Not Anti-DSG1 Antibody, After Cessation of Sitagliptin Treatment in a Patient With Pemphigus Vulgaris. JAMA Dermatol. 2019;155(3):391–393. doi:10.1001/jamadermatol.2018.5379
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.